New to peptides? Start with the foundations ->
The dad-test answer
Topical GHK-Cu is the form with actual skin and hair clinical evidence behind it - it's been in cosmetic dermatology for decades. Injectable GHK-Cu is a research-use protocol with thinner human evidence; most operators using GHK-Cu for systemic anti-aging effects are extrapolating from animal data and Pickart's review papers.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| skin firmness, fine lines, photodamage |
topical serum Multiple peer-reviewed cosmeceutical trials show measurable improvement in collagen density and skin elasticity with topical GHK-Cu serums. |
| wound healing, scar remodeling |
topical (locally) or injection (deep) Topical for surface wounds; injection considered for deeper tissue but evidence is animal-grade. |
| hair regrowth and follicle support |
topical Pickart's papers and follow-up cosmetic trials show follicle-density signal with topical formulations. |
| systemic anti-aging signaling |
injection (with caveats) Animal evidence supports the systemic case but human trial evidence is sparse - this is biohacker territory. |
What the head-to-head data shows
GHK-Cu (copper tripeptide-1) was characterized by Pickart in the 1970s and has been used in cosmetic dermatology for decades. Pickart and Margolina 2012 reviews the molecule's signaling effects on wound healing, collagen synthesis, and gene expression. Multiple peer-reviewed cosmeceutical trials show measurable skin firmness and collagen-density improvements with topical 1-2% GHK-Cu serums over 12-week protocols. Injectable GHK-Cu is research-use - the systemic anti-aging case rests on animal models and Pickart's gene-expression papers showing modulation of about 4,000 human genes (Pickart and Margolina 2018), but human clinical trials at the systemic dose are sparse.
Our honest call
For skin firmness, fine lines, photodamage, scar remodeling, or hair density work, topical 1-2% GHK-Cu serum is the form with the actual evidence behind it - and the skin is the target tissue, so local delivery makes sense. Read the GHK-Cu topical skin protocol for the 12-week plan. Injectable GHK-Cu for systemic anti-aging is a biohacker move that rests on animal data and gene-expression papers, not human trials. We are not against people running it - we are honest that the evidence tier drops a step when you go systemic. Read the full GHK-Cu dosing breakdown for both routes.
Sources and citations
- Pickart and Margolina, GHK peptide review, Int J Mol Sci 2012 (PMID 22928174)
- Pickart and Margolina, GHK gene expression review, Int J Mol Sci 2018 (PMID 29487424)
- Cosmetic Bioscience peer-reviewed cosmeceutical trials (Skin Pharmacol Physiol 2010s)
- Compounding pharmacy formularies (Tailor Made, Empower)
Where to go next
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.